Detailed narrative
Preservative-Free Ketamine ANDA Progress
The company completed the first review cycle for its preservative-free ketamine ANDA, resolving the single major deficiency related to the Luer lock component of the vial. This attestation has been provided to the FDA, and the company aims for 2026 approval. To support this, 5 million units of launch stock have been ordered from the manufacturer, targeting a current market of $750 million for hospital and clinic use.
NRX-100 NDA Advancement with Real-World Evidence
NRX-100, an NDA for depression, is advancing towards a 2027 approval target. This progress is significantly supported by a presidential executive order and congressional budget language guiding the FDA to use real-world evidence for approval of ketamine and other psychedelic products. Evidence gathered from 65,000 Americans demonstrated intravenous ketamine's comparable efficacy and more rapid onset than intranasal S-ketamine.
NRX-101 Market Expansion via SPARC-TMS Trial
NRX-101's market is potentially expanding beyond suicidal bipolar depression to all treatment-resistant depression, an addressable market of over 15 million Americans. NRx was selected as a prime contractor by DARPA for the FDA-approved Phase II/III SPARC-TMS trial, combining NRX-101 with robotic TMS. This trial, involving 240 patients at HOPE clinics/Harvard/McLean and 160 at military facilities, is federally funded and aims to provide a short-term, effective treatment for military personnel and first responders.
Acquisition of GeNeuro Assets and ALS Program
The acquisition of GeNeuro assets was finalized in June, bringing two clinical-stage monoclonal antibodies into NRx's portfolio. GNK-301, targeting HERV-K envelope protein for ALS, was coinvented with NIH and has received initial funding selection from the congressionally-directed medical research program. The first-in-human trial for GNK-301 is targeted for July 2027, with substantial additional funding potentially available in the 2027 defense appropriation.
Temelimab and Schizophrenia/Psychosis Research
The GeNeuro acquisition also includes temelimab, a monoclonal antibody that has shown effects in multiple sclerosis and type 1 diabetes. Research by Fondation FondaMental suggests a role for temelimab in treating schizophrenia and other psychoses associated with the HERV-W envelope protein, found in up to 50% of acute psychosis patients. GeNeuro aims to partner with Fondation FondaMental to launch a clinical trial for temelimab in schizophrenia.
HOPE Therapeutics Network Expansion
The HOPE Therapeutics network continues to expand, now operating 5 clinical locations in Florida. The SPARC-TMS trial's focus on neuronavigation, robotic TMS, and neuroplastic-assisted care provides a unique platform for HOPE Therapeutics to demonstrate superior results in a shorter timeframe compared to traditional handheld TMS, aiming for clinical excellence and compassionate care.
Financial Overview and Capital Allocation
For the first half of FY26, NRx reported a net loss of $18 million and a net operating loss of $11.3 million, primarily due to increased R&D and SG&A for anticipated commercial launches. The company's cash and cash equivalents significantly increased to $26.7 million as of June 30, 2026, from $7.8 million at year-end 2025, following a public offering that generated over $22 million in gross proceeds. Management believes current cash resources, along with anticipated launch revenue and ATM facility utilization, will support operations for at least a year.